|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0027022,
umls-concept:C0032854,
umls-concept:C0035647,
umls-concept:C0054173,
umls-concept:C0079460,
umls-concept:C0178602,
umls-concept:C0205195,
umls-concept:C0243095,
umls-concept:C0281375,
umls-concept:C1274040,
umls-concept:C1561558,
umls-concept:C2603343
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-12-20
|
|
pubmed:abstractText |
Pharmacologic differentiating agents have had relatively limited clinical success outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be enhanced in combination with lineage-specific growth factors. We developed a dose finding trial to assess toxicity, differentiating activity, and clinical impact of the combination of bryostatin-1 and GM-CSF.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-11090046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-12114217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-12432257,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-12538458,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-14673054,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-15649387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-15755292,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-16042686,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-1800630,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-1995093,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-2033960,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-2310830,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-2350571,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-2455568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-2506950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-2753943,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-2786688,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-2917358,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-2996535,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-3317410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-3907633,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-7670135,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-9207439,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-9554585,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-9607591,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-9615391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-9653932,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598742-9852076
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
pubmed-author:BakerSharyn DSD,
pubmed-author:BlumenthalGideonG,
pubmed-author:BrodskyRobert ARA,
pubmed-author:ChoEunpiE,
pubmed-author:GoreSteven DSD,
pubmed-author:JonesRichard JRJ,
pubmed-author:KarpJudith EJE,
pubmed-author:KowalskiJeanneJ,
pubmed-author:MatsuiWilliam HWH,
pubmed-author:MeadeBrookeB,
pubmed-author:MurgoAnthonyA,
pubmed-author:PiantadosiStevenS,
pubmed-author:RudekMichelle AMA,
pubmed-author:SmithB DouglasBD,
pubmed-author:ValaMiladaM,
pubmed-author:WarlickErica DED,
pubmed-author:ZhangZheZ,
pubmed-author:ZhaoMingM
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
87-94
|
|
pubmed:dateRevised |
2011-7-25
|
|
pubmed:meshHeading |
pubmed-meshheading:20598742-Adult,
pubmed-meshheading:20598742-Aged,
pubmed-meshheading:20598742-Antineoplastic Agents,
pubmed-meshheading:20598742-Bryostatins,
pubmed-meshheading:20598742-Cell Differentiation,
pubmed-meshheading:20598742-Dose-Response Relationship, Drug,
pubmed-meshheading:20598742-Female,
pubmed-meshheading:20598742-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:20598742-Humans,
pubmed-meshheading:20598742-Male,
pubmed-meshheading:20598742-Middle Aged,
pubmed-meshheading:20598742-Prognosis
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.
|
|
pubmed:affiliation |
Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA. bdsmith@jhmi.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
